Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
Phase 4 N=41 Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words
Phase 2 N=68 Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
N/A N=30 Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Phase 2 N=51 Smell in Covid-19 and Efficacy of Nasal Theophylline
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
N/A N=29 Olfactory Contributions to Sleep-dependent Food Craving
Sleep Deprivation
Primary: Functional Magnetic Resonance Imaging (fMRI)-Based Decoding Accuracy of Food vs Non-food Odors in Piriform Cortex — 54.38; 49.65 Percentage correctly classified — p=0.001
Phase 4 N=102 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
Phase 2 N=15 Directed Topical Drug Delivery for Treatment for PASC Hyposmia
Post Acute Sequelae Covid-19 Hyposmia
Primary: Percentage of Participants Achieving MCID (Minimal Clinically Important Difference) on the Smell Identification Test (SIT) — 66.70; 28.57; 66.70; 42.86 percentage of…
Phase 2 N=7 Helping Olfaction and Nutrition On Renal Replacement
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
N/A N=125 Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions
Nutritional and Metabolic Diseases
Primary: Gut Microbiome — 52; 64; 25; 33 Normalized OTU counts
Phase 2 N=41 Oxytocin Administration in BDD and OCD
Body Dysmorphic Disorder · Obsessive-compulsive Disorder
Primary: Emotion Recognition Questionnaire — 18.67; 17.00; 17.00; 16.40 score on a scale
N/A N=16 Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
Nutritional and Metabolic Diseases
Primary: Number of Test Results Outside the Normal Range — 6; 3; 0; 0 participants
Phase 2 N=11 Oxytocin and Stress Response in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging…
Phase 2 N=30 Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants
N/A N=39 Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Nutritional and Metabolic Diseases
Primary: Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls. — 3.4; 8.6; 0.443; 0.8 uMol/mM creatinine
Phase 2 N=22 Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
Nonallergic Irritant Rhinitis
Primary: Change in Total Symptom Score — -5; 2 score on a scale
Phase 2 N=40 SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Rhinitis
Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…
Phase 2 N=58 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Mood Disorder · Disruptive Behavior Disorders
Primary: Change in Affective Reactivity Index - Youth (ARI-Y) — -2.9; -0.8 score on a scale
N/A N=49 Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol — 2.61; 1.66; 2.23; 2.69 mM — p=0.001
Phase 2 N=100 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week